Patents further strengthen intellectual property surrounding Company’s lead commercial product, CGuard™
EPS
InspireMD remains on track to submit an Investigational Device Exception (IDE) with FDA in
mid-2019
TEL AVIV, Israel, Sept. 17, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic
Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that the
United States Patent and Trademark Office (USPTO) has issued US Patents 10,070,976 and 10,070,977 covering InspireMD’s proprietary
MicroNet™ stent jacket combined with a stent scaffold and related drug eluting technologies. MicroNet is a key differentiator of
InspireMD’s commercial products, including the company’s lead product, CGuard™ EPS, for the prevention of stroke in patients being
treated for carotid artery disease. The claims also cover MGuard Prime™ EPS for patients being treated for acute myocardial
infarction.
“We are pleased that the USPTO has recognized this unique technology that we believe can revolutionize the field of vascular
stenting in general, but more importantly, prevent stroke in patients with carotid artery disease,” said James Barry, PhD, Chief
Executive Officer of InspireMD. “Conventional stenting in patients being treated for carotid artery disease allows for the
protrusion of plaque through the stent struts and into the blood vessel in up to 65% of cases, significantly increasing the risk of
stroke and other complications post-procedure. However, our novel MicroNet stent jacket technology acts as a safety net that
prevents debris from passing through the mesh, resulting in significantly lower complication rates versus conventional stenting.
These patents also strengthen and broaden our overall product and technology portfolio with the inclusion of claims covering drug
eluting technologies. Combining MicroNet with drug eluting capabilities would be a key differentiating feature of our coronary
stent product, MGuard Prime EPS, and any other drug eluting stent product, creating what we believe are broad potential
applications in the coronary drug eluting stent market.”
Dr. Barry continued, “We look forward to further executing on our growth strategy, which includes the expansion of our
commercial footprint, both in countries where we have established distribution as well as new geographies. We are also working to
submit a U.S. investigational device exception (IDE) for CGuard EPS to FDA expected in mid-2019 as we begin the process of
accessing the U.S. Market.”
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for Carotid Stenting by
providing outstanding acute results and durable stroke free long-term outcomes.
InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE
American under the ticker symbol NSPR.WS.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified
and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing
and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure
regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger,
multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and
reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party
payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our
products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign
jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise
additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or
difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency
exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and
political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may
affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com
